 "dr reddy's laboratory , dr reddy , drl pharma sector")
Dr Reddy's Laboratories on Wednesday reported a 1 per cent increase in consolidated net profit to ₹1,410 crore during the Juen quarter.
The Hyderabad-based drug major reported a net profit of ₹1,392 crore in the year-ago period.
Revenue increased to ₹8,545 crore in he period under review from ₹7,673 crore a year earlier.
"We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio," Dr Reddy's Co-Chairman & MD G V Prasad said.
The pricing pressure on Lenalidomide is expected to intensify in the US generics market, he noted.
"We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development," Prasad said.
Shares of the company ended 0.58 per cent up at ₹1,247.55 apiece on the BSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
 "The aspirations of a young India and increased income levels have encouraged companies to consider mergers and acquisitions (M&A) to keep up with demand. In a world where consumer preferences change dramatically, M&As provide companies the means to r")
 "Pizza Hut")
 "RIL, Reliance, Reliance Industries")
 "Myntra")
